

SEQUENCE LISTING

<110> NERI, DARIO
 TARLI, LORENZO
 VITI, FRANCESCA
 BIRCHLER, MANFRED

<120> SPECIFIC BINDING MOLECULES FOR SCINTIGRAPHY, CONJUGATES
 CONTAINING THEM AND THERAPEUTIC METHOD FOR TREATMENT OF
 ANGIOGENESIS

<130> ELLIS-0002-P02-C01

<140> 10/821,930
 <141> 2004-04-12

<150> 09/512,082
 <151> 2000-02-24

<150> 09/300,425
 <151> 1999-04-28

<150> 09/075,338
 <151> 1998-05-11

<160> 34

<170> PatentIn version 3.5

<210> 1
 <211> 24
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 primer

<400> 1
 gcggcccagc cggccatggc cgag
 24

<210> 2
 <211> 54
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 primer

<220>
 <221> modified_base
 <222> (24)..(25)
 <223> a, c, t, g, unknown or other

<220>
 <221> modified_base
 <222> (27)..(28)
 <223> a, c, t, g, unknown or other

<220>
 <221> modified_base
 <222> (30)..(31)

<223> a, c, t, g, unknown or other

<400> 2

gagcctggcg gacccagctc atmnnmnnmn ngctaaaggt gaatccagag gctg
54

<210> 3

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
primer

<400> 3

atgagctggg tccgccagge tcc
23

<210> 4

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
primer

<220>

<221> modified_base

<222> (23)..(24)

<223> a, c, t, g, unknown or other

<220>

<221> modified_base

<222> (32)..(33)

<223> a, c, t, g, unknown or other

<220>

<221> modified_base

<222> (38)..(39)

<223> a, c, t, g, unknown or other

<400> 4

gtctgcgtag tatgtgttac cmnnactacc mnaatmnnt gagaccact ccagcccctt
60

<210> 5

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
primer

<400> 5

acatactacg cagactccgt gaag
24

<210> 6

<211> 53
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
primer

<400> 6
tcattctcga cttgcggccg ctttgatttc caccttggtc ccttggccga acg
53

<210> 7
<211> 47
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
primer

<220>
<221> modified_base
<222> (24)..(25)
<223> a, c, t, g, unknown or other

<400> 7
gtttctgctg gtaccaggct aamngctgc tgctaact ctgactg
47

<210> 8
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
primer

<400> 8
ttagcctggc accagcagaa acc
23

<210> 9
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
primer

<220>
<221> modified_base
<222> (23)..(24)
<223> a, c, t, g, unknown or other

<400> 9
gccagtggcc ctgctggatg cmnnatagat gaggagcctg ggagcc
46

<210> 10
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
primer

<400> 10
gcatccagca gggccactgg c
21

<210> 11
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
primer

<400> 11
gcggcccagc atgccatggc cgaggtgcag ctgttggagt ctggg
45

<210> 12
<211> 55
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
primer

<220>
<221> modified_base
<222> (26)..(27)
<223> a, c, t, g, unknown or other

<220>
<221> modified_base
<222> (29)..(30)
<223> a, c, t, g, unknown or other

<220>
<221> modified_base
<222> (32)..(33)
<223> a, c, t, g, unknown or other

<220>
<221> modified_base
<222> (35)..(36)
<223> a, c, t, g, unknown or other

<400> 12
ggttccctgg cccagtagt caaamnnmnn mnnmnnntttc gcacagtaat atacg
55

<210> 13
<211> 24

<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
primer

<400> 13
gcggcccagc atgcatggc cgag
24

<210> 14
<211> 66
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
primer

<400> 14
cccgtaccg ccactggacc catcgccact cgagacggtg accaggggtc cctggcccca
60

gtagtc
66

<210> 15
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
primer

<400> 15
gatgggtcca gtggcggtag cggggg'gcgcg tcgactggcg aaattgtgtt gacgcagtct
60

cc
62

<210> 16
<211> 63
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
primer

<220>
<221> modified_base
<222> (26)..(27)
<223> a, c, t, g, unknown or other

<220>
<221> modified_base
<222> (32)..(33)
<223> a, c, t, g, unknown or other

<220>
 <221> modified_base
 <222> (35)..(36)
 <223> a, c, t, g, unknown or other

<220>
 <221> modified_base
 <222> (41)..(42)
 <223> a, c, t, g, unknown or other

<400> 16
 caccttggtc ccttggccga acgtmnnccg mnnmnnaccm nctgctgac agtaatacac
 60

tgc
 63

<210> 17
 <211> 56
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 primer

<400> 17
 gagtcattct cgacttgccg ccgctttgat ttccaccttg gtcccttggc cgaacg
 56

<210> 18
 <211> 24
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 primer

<400> 18
 gatgggtcca gtggcggtag cggg
 24

<210> 19
 <211> 116
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 H antibody specific for ED-B domain of fibronectin

<400> 19
 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe
 20 25 30

Ser Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Ser Ile Ser Gly Ser Ser Gly Thr Thr Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Lys Pro Phe Pro Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val
100 105 110

Thr Val Ser Ser
115

<210> 20

<400> 20
000

<210> 21

<400> 21
000

<210> 22

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide formula

<400> 22

Glu Gly Ile Pro Ile Phe Glu Asp Phe Val Asp Ser Ser Val Gly Tyr
1 5 10 15

<210> 23

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide formula

<400> 23

Tyr Thr Val Thr Gly Leu Glu Pro Gly Ile Asp Tyr Asp Ile Ser
1 5 10 15

<210> 24

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide formula

<400> 24

Asn Gly Gly Glu Ser Ala Pro Thr Thr Leu Thr Gln Gln Thr
1 5 10

<210> 25

<211> 72

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
DNA construct

<220>

<221> CDS

<222> (10)..(69)

<400> 25

gcggccgcga gat gac gat tcc gac gat gac tac aag gac gac gac gac aag
51

Asp Asp Asp Ser Asp Asp Asp Tyr Lys Asp Asp Asp Asp Lys
1 5 10

cac cat cac cat cac cat tag

72

His His His His His His

15 20

<210> 26

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide construct

<400> 26

Asp Asp Asp Ser Asp Asp Asp Tyr Lys Asp Asp Asp Asp Lys His His
1 5 10 15

His His His His

20

<210> 27

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
anti-ED-B antibody clone

<400> 27

Ala Ile Ser Gly Ser Gly

1 5

<210> 28
 <211> 6
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 anti-ED-B antibody clone

 <400> 28
 Ser Ile Arg Gly Ser Ser
 1 5

 <210> 29
 <211> 4
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 anti-ED-B antibody clone

 <400> 29
 Gly Leu Ser Ile
 1

 <210> 30
 <211> 4
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 anti-ED-B antibody clone

 <400> 30
 Ser Phe Ser Phe
 1

 <210> 31
 <211> 4
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 anti-ED-B antibody clone

 <400> 31
 Phe Pro Phe Tyr
 1

 <210> 32
 <211> 6
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 anti-ED-B antibody clone

 <400> 32

Asn Gly Trp Tyr Pro Trp
1 5

<210> 33
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
anti-ED-B antibody clone

<400> 33
Gly Gly Trp Leu Pro Tyr
1 5

<210> 34
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
anti-ED-B antibody clone

<400> 34
Thr Gly Arg Ile Pro Pro
1 5